Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients

Effect of Nitrate Supplementation on Blood Pressure and Systemic Microvascular Function of Resistant Hypertensive Patients

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06169241

Enrollment

Registered

2023-12-13

Start date

2023-11-01

Completion date

2026-12-01

Last updated

2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Hypertension, Microvascular Function, Nitrate Supplementation, Resistant Hypertension

Keywords

microcirculation, capillary density, microvascular reactivity, systemic resistant hypertension

Brief summary

Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.

Interventions

DIETARY_SUPPLEMENTBeetroot extract

Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.

DIETARY_SUPPLEMENTPlacebo

The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Treatment with beetroot extract powder - nutritional supplementation

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Resistant hypertension, with a diagnosis described in the medical record, without changing medications or increasing doses in the last 30 days.

Exclusion criteria

* neoplasms * heart failure * use of medications with nitrate in their formula * patients undergoing renal denervation

Design outcomes

Primary

Measure	Time frame	Description
Assessment of blood pressure evolution	60 days	Evaluation using Ambulatory Blood Pressure Monitoring: systolic, diastolic and mean arterial pressures

Countries

Brazil

Contacts

CONTACTEDUARDO TIBIRICA, MD, PhD

etibi@uol.com.br+55-21-99914-6075

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026